{
    "Trade/Device Name(s)": [
        "RapidOne-Buprenorphine Test"
    ],
    "Submitter Information": "American BioMedica Corporation",
    "510(k) Number": "K060760",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "June 23, 2006",
    "Summary Letter Received Date": "June 28, 2006",
    "Submission Date": "March 13, 2006",
    "Regulation Number(s)": [
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Buprenorphine",
        "Buprenorphine glucuronide"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay",
        "Competitive immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for RapidOne-Buprenorphine Test, a lateral flow immunoassay for qualitative detection of buprenorphine in human urine",
    "Indications for Use Summary": "Qualitative screening for buprenorphine and buprenorphine glucuronide in human urine, providing preliminary results to determine need for confirmatory LC/MS testing; intended for professional use only",
    "fda_folder": "Toxicology"
}